FDA approves Roche’s Tecentriq plus chemotherapy for adjuvant stage III dMMR colon cancer

• FDA cleared Tecentriq, including Tecentriq Hybreza, with fluoropyrimidine-oxaliplatin chemo for adjuvant stage III dMMR colon cancer.
• Phase III ATOMIC trial showed a 50% cut in recurrence or death risk versus mFOLFOX6 alone; 36-month DFS 86% vs 76%.
• U.S. study was sponsored by the National Cancer Institute, led by Alliance for Clinical Trials in Oncology; Genentech supported via a CRADA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20261009492482) on October 09, 2026, and is solely responsible for the information contained therein.